Study on the Safety and Efficacy of Empasiprubart for Adults with Dermatomyositis

2 1

What is this study about?

This clinical trial is focused on studying a condition called Dermatomyositis, which is a rare inflammatory disease that affects the skin and muscles. The study will evaluate a treatment called Empasiprubart, also known by its code name ARGX-117. This treatment is given as a concentrate for solution for infusion, meaning it is administered directly into the bloodstream through a vein. The purpose of the study is to assess the safety and tolerability of Empasiprubart compared to a placebo in adults with Dermatomyositis.

Participants in the study will receive either Empasiprubart or a placebo. The study is designed to be double-blinded, which means neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not biased. The study will take place over a period of up to 90 weeks, with participants being monitored for any adverse events, which are any unwanted effects that might occur during the study. The study will also measure how many participants stop taking the study medication due to these adverse events within the first 25 weeks.

Throughout the study, researchers will also evaluate the improvement in participants’ conditions using a measure called the Total Improvement Score (TIS) at specific intervals, such as weeks 13 and 25. This score helps determine how well the treatment is working in improving the symptoms of Dermatomyositis. The study aims to provide valuable information on the potential benefits and risks of using Empasiprubart as a treatment option for this condition.

1 initial assessment

Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying a diagnosis of dermatomyositis and ensuring compliance with background treatment requirements.

Participants must have received specific vaccinations at least 14 days before the first administration of the study drug.

2 randomization and treatment assignment

Participants are randomly assigned to receive either the study drug empasiprubart or a placebo. This process is double-blinded, meaning neither the participant nor the study team knows which treatment is being administered.

3 treatment administration

The study drug, ARGX-117, or placebo is administered through an intravenous infusion. The frequency and dosage are determined by the study protocol and are monitored by the study team.

4 monitoring and follow-up

Participants are monitored for any adverse events throughout the study period, which can last up to 90 weeks. Regular follow-up visits are scheduled to assess safety and tolerability.

The primary focus is on the incidence of adverse events and the percentage of participants discontinuing the treatment due to these events.

5 efficacy evaluation

The efficacy of the treatment is evaluated using the Total Improvement Score (TIS) at weeks 13 and 25. This score helps determine the effectiveness of the treatment in improving symptoms of dermatomyositis.

6 study completion

Upon completion of the study, participants undergo a final assessment to evaluate overall outcomes and any long-term effects of the treatment.

Who Can Join the Study?

Must be at least 18 years old and meet the local legal age for giving consent to participate in clinical studies.
Must be able to provide signed consent and follow the study’s rules.
Must agree to use birth control methods as required by local laws. Women who can have children must have a negative pregnancy test before starting the study.
Must have a clinical diagnosis of dermatomyositis or juvenile dermatomyositis. If diagnosed with juvenile dermatomyositis, it should have been diagnosed 5 years or less before joining the study.
Must have active muscle disease related to classic dermatomyositis or juvenile dermatomyositis. This means having at least one of the following: high levels of certain enzymes in the blood (like creatine kinase, aldolase, lactate dehydrogenase, aspartate aminotransaminase, or alanine aminotransferase), an electromyography test showing muscle issues, an MRI showing muscle inflammation, or a muscle biopsy showing active inflammation, all within 18 weeks before starting the study.
Must have at least mild skin disease at the time of joining the study.
Must follow the allowed treatments for dermatomyositis at the time of joining the study.
Must have received certain vaccines (meningococcal, pneumococcal, and Haemophilus influenza type B) at least 14 days before starting the study.

Who Cannot Join the Study?

Patients who have a different condition than dermatomyositis cannot participate. Dermatomyositis is a condition that causes muscle weakness and skin rash.
Patients who are not adults are excluded. This means only people who are 18 years or older can join.
Patients who are not able to understand or follow the study instructions will not be able to participate.
Patients who have other serious health issues that might interfere with the study will be excluded.
Patients who are pregnant or breastfeeding cannot take part in the study.
Patients who are currently participating in another clinical trial are not allowed to join.
Patients who have had a recent change in their medication for dermatomyositis may not be eligible.
Patients who have a history of allergic reactions to similar medications will be excluded.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu	Wroclaw	Poland

Other Sites

Site Name	City	Country
Azienda Ospedaliero-Universitaria Sant Andre	Rome	Italy
Hospital Del Mar	Barcelona	Spain
Hospital Universitario Rio Hortega	Valladolid	Spain
Nova Reuma Domyslawska I Rusilowicz Lekarza Reumatologa I Fizjoterapeuty sp.p.	Bialystok	Poland
General Hospital Of Thessaloniki Papageorgiou	Thessaloniki	Greece
Universita’ Campus Bio-medico Di Roma	Rome	Italy
Universita’ Di Pisa	Pisa	Italy
Andreas Syngros Hospital Of Venereal And Dermatological Diseases	Athens	Greece
Pcqxchev Pgidwftx Lfhnxfmq Pauq Df Hvl Mby Pebfa Hojwbv	Poznan	Poland
Ablzhxn Ujyrz Sxvlfruae Lnyume Db Bjbjmdt	Bologna	Italy
Uojdznzxos Gsgarew Hzocqzaj Aavrhsh	Athens	Greece

Trial status

Country	Status	Recruitment Start
Greece	Not recruiting	01.02.2025
Italy	Not recruiting	01.02.2025
Poland	Not recruiting	01.02.2025
Spain	Not recruiting	01.02.2025

Trial locations

Investigated drugs:

Empasiprubart

Empasiprubart is a medication being studied for its potential to help adults with dermatomyositis, a condition that causes muscle weakness and skin rashes. The trial aims to see how safe and tolerable this medication is for patients, as well as how effective it might be in treating the symptoms of dermatomyositis.

Investigated diseases:

Dermatomyositis

Dermatomyositis – Dermatomyositis is an inflammatory disease characterized by muscle weakness and a distinctive skin rash. The condition primarily affects the muscles and skin, leading to symptoms such as muscle pain, fatigue, and difficulty with physical activities. The skin rash often appears as a purplish or red discoloration, typically on the face, knuckles, and other areas exposed to sunlight. Over time, the muscle weakness can progress, affecting the ability to perform everyday tasks. The exact cause of dermatomyositis is not well understood, but it is believed to involve an autoimmune response. The disease can vary in severity, with some individuals experiencing mild symptoms and others facing more significant challenges.

Trial ID:

2023-508337-14-00

Protocol code:

ARGX-117-2301

NCT ID:

NCT06284954

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on the Safety and Efficacy of Empasiprubart for Adults with Dermatomyositis

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?